{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:06:58Z","timestamp":1740146818612,"version":"3.37.3"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019408","name":"Marcus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019408","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aid L Shalom"},{"name":"MZB Foundation for Cancer Research"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nPatients have difficult unmet needs when standard chemotherapy produces a median survival of less than 1 year or many patients will experience severe toxicities. Blood tests can predict their survival.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nAnalyses evaluate predictive blood tests to identify patients who often survive 1 and 2 years. A four-test model includes: albumin, absolute neutrophil count, neutrophil-lymphocyte ratio, and lymphocyte-monocyte ratio. Individual tests include: alkaline phosphatase, lymphocytes, white blood count, platelet count, and hemoglobin. Eligible patients have advanced: resistant 3rd<\/jats:sup> line colorectal, and both resistant and new pancreatic and intrahepatic bile duct cancers. Eligibility characteristics include: biopsy-proven, measurable metastatic disease, NCI grade 0\u20132 blood tests, Karnofsky Score 100\u201350, and any adult age. Drugs are given at 1\/4\u20131\/3 of their standard dosages biweekly: gemcitabine, irinotecan, fluorouracil, leucovorin, and day 2 oxaliplatin every 2 weeks. In case of progression, Docetaxel is added (except colon cancer), with or without Mitomycin C, and next cetuximab (except pancreatic and KRAS BRAF mutation cancers). Bevacizumab is substituted for cetuximab in case of another progression or ineligibility. Consent was written and conforms with Helsinki, IRB, and FDA criteria (FDA #119005).<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nMedian survival is 14.5 months. Of 205 patients, 60% survive 12, and 37% survive 24 months (95% CI \u00b1 8%). Survival is > 24, 13, and 3.8 months for patients with 0, 1\u20132, and 3\u20134 unfavorable tests, respectively. Individual \u201cfavorable and unfavorable\u201d tests predict long and short survival. Neither age nor prior therapy discernibly affects survival. Net rates of clinically significant toxicities are less than 5%.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nTreatments reproduce predictable, greater than 12 and 24-month chances of survival for the aged and for patients with drug-resistant tumors. Evaluation of blood tests may change practice, expand eligibility, and personalize treatments. Findings support investigation of drug combinations and novel dosages to reverse resistance and improve safety.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0276492","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T18:01:09Z","timestamp":1667412069000},"page":"e0276492","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-7255","authenticated-orcid":true,"given":"Howard W.","family":"Bruckner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Bassali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisheva","family":"Dusowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gurell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abe","family":"Book","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"1","key":"pone.0276492.ref001","first-page":"399","article-title":"Targeted therapy for resistant cholangiocarcinoma with bevacizumab or cetuximab added to failed cytotoxic drug cores","volume":"36","author":"HW Bruckner","year":"2016","journal-title":"Anticancer research"},{"issue":"1","key":"pone.0276492.ref002","first-page":"547","article-title":"Bevacizumab added to moderate-dose chemotherapy for refractory uterine cancer","volume":"38","author":"HW Bruckner","year":"2018","journal-title":"Anticancer research"},{"issue":"6","key":"pone.0276492.ref003","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1879-4068(19)31181-6","article-title":"Moderate Dose Sequential Chemotherapy (CT) Algorithms (ALGOS) for the Elderly with and without Resistant Cancers (RC)","volume":"10","author":"HW Bruckner","year":"2019","journal-title":"Journal of Geriatric Oncology"},{"issue":"19","key":"pone.0276492.ref004","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"T Conroy","year":"2011","journal-title":"New England journal of medicine"},{"issue":"1","key":"pone.0276492.ref005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2010.10.009","article-title":"Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer","volume":"80","author":"J Furuse","year":"2011","journal-title":"Critical reviews in oncology\/hematology"},{"issue":"20","key":"pone.0276492.ref006","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"RJ Mayer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"pone.0276492.ref007","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"DD Von Hoff","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"pone.0276492.ref008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"A Wang-Gillam","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"27","key":"pone.0276492.ref009","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"E Van Cutsem","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0276492.ref010","doi-asserted-by":"crossref","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: A population-based modelling study","volume":"47","author":"E Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"22","key":"pone.0276492.ref011","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"SG Mohile","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"pone.0276492.ref012","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience","volume":"18","author":"JE Faris","year":"2013","journal-title":"The oncologist"},{"issue":"1","key":"pone.0276492.ref013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer facts & figures 2020","volume":"70","author":"RL Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"journal-title":"Global Cancer Facts and Figures","year":"2021","key":"pone.0276492.ref014"},{"issue":"2","key":"pone.0276492.ref015","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4049\/jimmunol.175.2.820","article-title":"Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro","volume":"175","author":"P Correale","year":"2005","journal-title":"The Journal of Immunology"},{"key":"pone.0276492.ref016","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fonc.2019.01102","article-title":"GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up","volume":"9","author":"M Caraglia","year":"2019","journal-title":"Frontiers in oncology"},{"key":"pone.0276492.ref017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11523-018-0572-3","article-title":"Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis","volume":"13","author":"WH Isacoff","year":"2018","journal-title":"Targeted oncology"},{"key":"pone.0276492.ref018","doi-asserted-by":"crossref","first-page":"e50036","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"AC Palmer","year":"2019","journal-title":"Elife"},{"issue":"10305","key":"pone.0276492.ref019","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"CK Chow","year":"2021","journal-title":"The Lancet"},{"issue":"7","key":"pone.0276492.ref020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jama.1982.03320320040027","article-title":"Absolute granulocyte, lymphocyte, and monocyte counts: useful determinants of prognosis for patients with metastatic cancer of the stomach","volume":"247","author":"HW Bruckner","year":"1982","journal-title":"Jama"},{"issue":"10","key":"pone.0276492.ref021","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(19821115)50:10<2016::AID-CNCR2820501007>3.0.CO;2-2","article-title":"Studies in prognostic factors relating to chemotherapy for advanced gastric cancer","volume":"50","author":"PT Lavin","year":"1982","journal-title":"Cancer"},{"issue":"33","key":"pone.0276492.ref022","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2009.21.9022","article-title":"Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment","volume":"27","author":"PA Philip","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"pone.0276492.ref023","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","article-title":"Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer","volume":"50","author":"MG McNamara","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"6","key":"pone.0276492.ref024","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"AJ Templeton","year":"2014","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"9","key":"pone.0276492.ref025","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/annonc\/mdv253","article-title":"Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies","volume":"26","author":"T Grenader","year":"2015","journal-title":"Annals of Oncology"},{"issue":"2","key":"pone.0276492.ref026","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.18632\/oncotarget.13731","article-title":"Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer","volume":"8","author":"KM Cho","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0276492.ref027","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2019.05.030","article-title":"The ALAN score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy","volume":"117","author":"M Salati","year":"2019","journal-title":"European Journal of Cancer"},{"key":"pone.0276492.ref028","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3389\/fimmu.2019.02155","article-title":"Neutrophil heterogeneity in cancer: From biology to therapies","volume":"10","author":"P Lecot","year":"2019","journal-title":"Frontiers in immunology"},{"key":"pone.0276492.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6180613","article-title":"Risk stratification in advanced biliary tract cancer: validation of the ALAN score","volume":"53","author":"L M\u00fcller","year":"2020","journal-title":"Journal of oncology"},{"issue":"1","key":"pone.0276492.ref030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"A Trotti","year":"2000","journal-title":"International Journal of Radiation Oncology* Biology* Physics"},{"issue":"6","key":"pone.0276492.ref031","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2004.02103.x","article-title":"The revision of the Declaration of Helsinki: past, present and future","volume":"57","author":"RV Carlson","year":"2004","journal-title":"British journal of clinical pharmacology"},{"issue":"1","key":"pone.0276492.ref032","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-018-3713-6","article-title":"Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?","volume":"83","author":"O K\u00f6stek","year":"2019","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"pone.0276492.ref033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"C Cremolini","year":"2019","journal-title":"JAMA oncology"},{"journal-title":"FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis","year":"2019","author":"MA Calegari","key":"pone.0276492.ref034"},{"issue":"11","key":"pone.0276492.ref035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.5306\/wjco.v11.i11.959","article-title":"Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review","volume":"11","author":"TP Reddy","year":"2020","journal-title":"World Journal of Clinical Oncology"},{"key":"pone.0276492.ref036","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/j.annonc.2021.08.938","article-title":"417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer","volume":"32","author":"M Puzzoni","year":"2021","journal-title":"Annals of Oncology"},{"key":"pone.0276492.ref037","article-title":"Laboratory based non-cross-resistant chemotherapy for pancreatic carcinoma","author":"H Bruckner","year":"2004","journal-title":"InAm S Clin Oncol Gastronintestinal Cancers Symposium"},{"key":"pone.0276492.ref038","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"RT Shroff","year":"2019","journal-title":"JAMA oncology"},{"key":"pone.0276492.ref039","doi-asserted-by":"crossref","first-page":"17588359211035983","DOI":"10.1177\/17588359211035983","article-title":"Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis","volume":"13","author":"J Cheon","year":"2021","journal-title":"Therapeutic advances in medical oncology"},{"key":"pone.0276492.ref040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","article-title":"Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity","volume":"76","author":"JC Lee","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"18_suppl","key":"pone.0276492.ref041","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1200\/jco.2006.24.18_suppl.14133","article-title":"Laboratory based low dose combination chemotherapy+ bevacizumab for recurrent refractory and unresectable gastric cancer","volume":"24","author":"HW Bruckner","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"pone.0276492.ref042","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1179\/joc.2006.18.5.545","article-title":"Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn\u2019s disease","volume":"18","author":"HW Bruckner","year":"2006","journal-title":"Journal of chemotherapy"},{"issue":"7","key":"pone.0276492.ref043","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2017-0561","article-title":"First report of dramatic tumor responses with ramucirumab and paclitaxel after progression on pembrolizumab in two cases of metastatic gastroesophageal adenocarcinoma.","volume":"23","author":"S Chakrabarti","year":"2018","journal-title":"The oncologist"},{"key":"pone.0276492.ref044","article-title":"Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn\u2019s Disease: A 9-Year Survival","author":"JP Kothadia","year":"2019","journal-title":"Case reports in oncological medicine"},{"key":"pone.0276492.ref045","doi-asserted-by":"crossref","first-page":"vi21","DOI":"10.1093\/annonc\/mdy314.002","article-title":"Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors","volume":"29","author":"IB Argota","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"pone.0276492.ref046","first-page":"3637","article-title":"Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer","volume":"25","author":"HW Bruckner","year":"2005","journal-title":"Anticancer research"},{"issue":"15_suppl","key":"pone.0276492.ref047","doi-asserted-by":"crossref","first-page":"15568","DOI":"10.1200\/jco.2008.26.15_suppl.15568","article-title":"Low-dose sequential multi-drug regimens for advanced pancreatic cancer","volume":"26","author":"H Bruckner","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0276492.ref048","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2017.35.15_suppl.e15711","article-title":"Broad safety impact of high-dose ascorbic acid and induction chemotherapy for high-risk pancreatic cancer","volume":"35","author":"H Bruckner","year":"2017","journal-title":"American Society of Clinical Oncology"},{"issue":"6","key":"pone.0276492.ref049","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S1879-4068(19)31196-8","article-title":"Moderate Sequential Third-To Fourth-Line Chemotherapy (CT) Algorithms (Algo) For the Elderly with Resistant Colorectal Cancer (R-CRC)","volume":"10","author":"R De Jager","year":"2019","journal-title":"Journal of Geriatric Oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T18:02:13Z","timestamp":1667412133000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276492"}},"subtitle":[],"editor":[{"given":"Md Sazzad","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276492","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}